Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury.

January 01, 2020 By:
  • Zhuang Y
  • Xu HC
  • Shinde PV
  • Warfsmann J
  • Vasilevska J
  • Sundaram B
  • Behnke K
  • Huang J
  • Hoell JI
  • Borkhardt A
  • Pfeffer K
  • Taha MS
  • Herebian D
  • Mayatepek E
  • Brenner D
  • Ahmadian MR
  • Keitel V
  • Wieczorek D
  • Haussinger D
  • Pandyra AA
  • Lang KS
  • Lang PA.

OBJECTIVE: The Fragile X mental retardation (FMR) syndrome is a frequently inherited intellectual disability caused by decreased or absent expression of the FMR protein (FMRP). Lack of FMRP is associated with neuronal degradation and cognitive dysfunction but its role outside the central nervous system is insufficiently studied. Here, we identify a role of FMRP in liver disease. DESIGN: Mice lacking Fmr1 gene expression were used to study the role of FMRP during tumour necrosis factor (TNF)-induced liver damage in disease model systems. Liver damage and mechanistic studies were performed using real-time PCR, Western Blot, staining of tissue sections and clinical chemistry. RESULTS: Fmr1(null) mice exhibited increased liver damage during virus-mediated hepatitis following infection with the lymphocytic choriomeningitis virus. Exposure to TNF resulted in severe liver damage due to increased hepatocyte cell death. Consistently, we found increased caspase-8 and caspase-3 activation following TNF stimulation. Furthermore, we demonstrate FMRP to be critically important for regulating key molecules in TNF receptor 1 (TNFR1)-dependent apoptosis and necroptosis including CYLD, c-FLIPS and JNK, which contribute to prolonged RIPK1 expression. Accordingly, the RIPK1 inhibitor Necrostatin-1s could reduce liver cell death and alleviate liver damage in Fmr1(null) mice following TNF exposure. Consistently, FMRP-deficient mice developed increased pathology during acute cholestasis following bile duct ligation, which coincided with increased hepatic expression of RIPK1, RIPK3 and phosphorylation of MLKL. CONCLUSIONS: We show that FMRP plays a central role in the inhibition of TNF-mediated cell death during infection and liver disease.

2020 Jan. Gut.69(1):133-145. Epub 2019 Aug 13.
Other information